Rituximab treatment in patients with systemic sclerosis and interstitial lung disease.

Ann Thorac Med 2017 Oct-Dec;12(4):294-297

Department of Medical Specialties, Rheumatology Section, King Fahad Medical City, Riyadh, KSA.

There is increasing interest in rituximab (RTX) as an alternative to cyclophosphamide for the treatment of interstitial lung diseases (ILDs) associated with systemic sclerosis (SSc). However, no report has addressed its efficacy in Saudi patients with SSc-ILD. To assess the efficacy of RTX treatment in Saudi patients with SSc-ILD, hospital records were reviewed between 2013 and 2016. Four female patients received at least 4 cycles of RTX (I cycle, consisting of two infusions of 1000 mg 2 weeks apart). Pulmonary function tests (PFTs) and chest high-resolution computed tomography (HRCT) were performed before and after treatment to assess the response. HRCT revealed improvement in one patient, stable disease in two patients, and worsening in one patient. Moreover, RTX prevented the further decline of forced vital capacity significantly in PFT. These results provide further evidence that RTX is an effective treatment for SSc-ILD.
PDF Download - Full Text Link
( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
Source Status
http://dx.doi.org/10.4103/atm.ATM_30_17DOI ListingPossible
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656950PMCFound
November 2017
3 Reads

Similar Publications

Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.

Arthritis Rheumatol 2015 Dec;67(12):3256-61

University Hospital Zurich, Zurich, Switzerland.

Objective: Validated methods for the screening and early diagnosis of systemic sclerosis (SSc; scleroderma)-related interstitial lung disease (ILD) are needed. The aim of this study was to evaluate the performance of pulmonary function tests (PFTs) compared with that of high-resolution computed tomography (HRCT) of the chest for the detection of SSc-related ILD in clinical practice, and to identify predictors of lung involvement that is functionally occult but significant on HRCT.

Methods: Prospectively enrolled patients with SSc were assessed according to the European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research standards. Read More

View Article
December 2015

Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.

Rheumatology (Oxford) 2015 Aug 3;54(8):1420-8. Epub 2015 Mar 3.

Institute of Clinical Medicine, Department of Rheumatology.

Objective: To retrospectively evaluate the efficacy and safety of rituximab (Rtx) treatment in patients with anti-synthetase syndrome (ASS) and severe interstitial lung disease (ILD).

Methods: Patients with severe ILD and >12 months follow-up post-Rtx were identified from the Oslo University Hospital ASS cohort (n = 112). Clinical data, including pulmonary function tests (PFTs), were retrospectively collected from medical reports. Read More

View Article
August 2015

Interstitial lung disease in systemic sclerosis.

Autoimmun Rev 2011 Mar 21;10(5):248-55. Epub 2010 Sep 21.

Université Paris Descartes, Institut Cochin, Inserm U1016, Paris, France.

Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc) and mainly encountered in patients with diffuse disease and/or anti-topoisomerase 1 antibodies. ILD develops in up to 75% of patients with SSc overall. However, SSc-ILD evolves to end-stage respiratory insufficiency in only a few patients. Read More

View Article
March 2011

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Rheumatology (Oxford) 2010 Feb 15;49(2):271-80. Epub 2009 May 15.

Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, 26504 Rion, Patras, Greece.

Objective: To assess the efficacy of rituximab (RTX) in SSc.

Methods: Fourteen patients with SSc were evaluated. Eight patients were randomized to receive two cycles of RTX at baseline and 24 weeks [each cycle consisted of four weekly RTX infusions (375 mg/m(2))] in addition to standard treatment, whereas six patients (control group) received standard treatment alone. Read More

View Article
February 2010